ARS Pharmaceuticals's total assets for Q1 2026 were $287.57M, a decrease of -12.23% from the previous quarter. SPRY total liabilities were $226.26M for the fiscal quarter, a 6.03% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.